This annual meeting is dedicated to fostering open dialogue and sharing experiences in navigating the complex regulatory and operational landscape of Early Access Programmes.
UK biopharma services company Ergomed will be taken into private hands with a takeover by a subsidiary of investment group Permira that values the company at around £703 m
We present the latest insight and analysis of the rapidly evolving field of cancer therapeutics and immuno-therapy, with a particular focus on what current innovati
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.
